刘伟,肖俊,兰金芝,曾智锐,雷珊,张金娟,陈腾祥
LIU Wei,XIAO Jun,LAN Jinzhi,ZENG zhirui,LEI Shan,ZHANG Jinjuan,CHEN Tengxiang

• 1:贵州医科大学
• 2:贵州医科大学基础医学院

摘要(Abstract)：

目的:观察人肝细胞株LO2及不同转移能力的肝癌细胞株Hep G2、MHCC-97L和LM3中组蛋白H3K9、H4K12及H4K16位点的乙酰化水平,并探讨组蛋白乙酰化对肝癌细胞迁移、侵袭能力的影响。方法:采用Western blot实验检测LO2、Hep G2、MHCC-97L和LM3中组蛋白H3K9、H4K12及H4K16乙酰化水平;应用组蛋白去乙酰化酶抑制剂伏立诺他(SAHA,1.5μmol/L和3μmol/L)处理肝癌LM3细胞株24 h、48 h后,Western blot检测其组蛋白H3K9、H4K12及H4K16乙酰化水平变化,transwell实验检测细胞迁移、侵袭能力的变化。结果:H3K9、H4K12及H4K16乙酰化水平由高到低为Hep G2、MHCC-97L、LM3,3种肝癌细胞株的乙酰化水平均低于人肝细胞LO2(P<0.05);去乙酰化酶抑制剂SAHA作用后,LM3细胞组蛋白H3K9、H4K12及H4K16乙酰化水平明显提高,细胞的迁移、侵袭能力明显降低,与未用SAHA处理的LM3细胞比较,差异有统计学意义(P<0.05)。结论:提高组蛋白H3K9、H4K12、H4K16位点的乙酰化水平,能抑制肝癌细胞的迁移、侵袭能力。
Objective: To observe the acetylation levels of histone H3 K9,H4 K12 and H4 K16 in hepatocellular carcinoma cells( HCC),and its effects on the motility and invasion of HCC. Methods:LO2,a normal liver cell line,and HEPG2,MHCC97 L,HCCLM3 with different metastasis potential,were detected by Western blot experiment to determine the histonhe acetylation levels of H3 K9,H4 K12 and H4 K16,the alteration of the acetylation after HCC were treated by suberoylanilide hydroxamic acid( SAHA),a acetylation inhibitor,for 24 h and 48 h. The migration and invasion ability of the cells were exploited by Transwell migration and Matrigell invasion assay after the cells were interfered with SAHA. Result: The acetylated levels of H3 K9,H4 K12 and H4 K16 were reduced to Hep G2,MHCC97 L and HCCLM3,compared with LO2; SAHA raised the acetylation levels of H3 K9,H4 K12 and H4 K16 in HCCLM3 and inhibited the mobility of HCC. Conclusion: The de-acetylation of H3 K9,H4 K12 and H4 K16 may involve in hepatoma 's occurrence and metastasis,and the migration and invasion of HCC can be inhibited by deacytlation inhibitor.

关键词(KeyWords)： 肝癌;组蛋白乙酰化;H3K9;H4K12;H4K16;迁移;侵袭
hepatoma;histone acetylation;H3K9;H4K12;H4K16;migration;invasion

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81060176);; 贵州省科技厅项目[黔科合LH(2014)7082,黔科合J字(2008)2280];; 贵州省教育厅自然科学研究项目[(2008)022号]

作者(Author): 刘伟,肖俊,兰金芝,曾智锐,雷珊,张金娟,陈腾祥
LIU Wei,XIAO Jun,LAN Jinzhi,ZENG zhirui,LEI Shan,ZHANG Jinjuan,CHEN Tengxiang

DOI: 10.19367/j.cnki.1000-2707.2017.12.001

参考文献(References)：

• [1]Gong F,Miller KM.Mammalian DNA repair:HATs and HDACs make their mark through histone acetylation[J].Mutat Res,2013(1-2):23-30.
• [2]Llovet JM.,Burroughs A,Bruix J.Hepatocellular carcinoma[J].Lancet,2003(9399):1907-1917.
• [3]Zhu RX.Epidemiology of hepatocellular carcinoma in the Asia-Pacific region[J].Gut Liver,2016(3):332-329.
• [4]Han Y,He X.Integrating epigenomics into the understanding of biomedical insight[J].Bioinform Biol Insights,2016(10):267-289.
• [5]Hardy T,Mann DA.Epigenetics in liver disease:from biology to therapeutics[J].Gut,2016(11):1895-1905.
• [6]Fraga MF,Esteller M.Towards the human cancer epigenome:a first draft of histone modifications[J].Cell Cycle,2005(10):1377-13781.
• [7]龚正鹏.HDAC1和SIRT1在喉鳞癌中的表达及意义[J].贵阳医学院学报,2013(4):356-358.
• [8]Mottamal M.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents[J].Molecules,2015(3):3898-3941.
• [9]Abdelfatah E.Epigenetic therapy in gastrointestinal cancer:the right combination[J].Therap Adv Gastroenterol,2016(4):560-579.
• [10]Zhang T.UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in Hep G2 hepatocellular carcinoma cells[J].Int J Mol Med,2017(1):126-134.
• [11]Yuan JH.The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma[J].Hepatology,2011(6):2025-2035.
• [12]Grabarska A.Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells[J].J Cancer,2017(1):19-28.

文章评论(Comment)：